| Literature DB >> 27342697 |
G B John Mancini1, Steven Baker2, Jean Bergeron3, David Fitchett4, Jiri Frohlich5, Jacques Genest6, Milan Gupta2, Robert A Hegele7, Dominic Ng4, Glen J Pearson8, Janet Pope7, A Yashar Tashakkor5.
Abstract
The Canadian Consensus Working Group has updated its evaluation of the literature pertaining to statin intolerance and adverse effects. This overview introduces a pragmatic definition of statin intolerance (goal-inhibiting statin intolerance) that emphasizes the effects of symptoms on achieving nationally vetted goals in patients fulfilling indications for lipid-lowering therapy and cardiovascular risk reduction. The Canadian Consensus Working Group provides a structured framework for avoiding, evaluating and managing goal-inhibiting statin intolerance. Particularly difficult practice situations are reviewed, including management in young and elderly individuals, and in athletes and labourers. Finally, targeted at specialty practitioners, more detailed analyses of specific but more unusual adverse effects ascribed to statins are updated including evidence regarding new-onset diabetes, cognitive dysfunction, cataracts, and the rare but important immune-mediated necrotizing myopathy.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27342697 DOI: 10.1016/j.cjca.2016.01.003
Source DB: PubMed Journal: Can J Cardiol ISSN: 0828-282X Impact factor: 5.223